Business
Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update
- FHD-909 (LY4050784) Phase 1 dose-escalation trial on track; preclinical combination data with anti-PD-1 antibody demonstrates potential for robust and durable regression with anti-tumor immune memory - Selective CBP degrader FHT-171 advancing for the treatment of ER+ breast cancer with IND anticipated in 2027 -Selective EP300 degraders with potential in multiple myeloma and other hematological malignancies with IND anticipated in 2027 - Strong balance sheet with cash, cash equivalents, and mar
About this update from Foghorn Therapeutics Inc.
[{"type":"image","alt":"Foghorn Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Foghorn Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":75,"url":"https://media.zenfs.com/en/globenewswire.com/c48e0461026ebce223e5a31638f2e086"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lZQs0UgtmfP013MY5QJUpg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNQ--/https://media.zenfs.com/en/globenewswire.com/c48e0461026ebce223e5a31638f2e086","width":300,"height":75},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/lZQs0UgtmfP013MY5QJUpg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNQ--/https://media.zenfs.com/en/globenewswire.com/c48e0461026ebce223e5a31638f2e086","width":300,"height":75}},"lazy":false},{"type":"text","content":"- FHD-909 (LY4050784) Phase 1 dose-escalation trial on track; preclinical combination data with anti-PD-1 antibody demonstrates potential for robust and durable regression with anti-tumor immune memory ","length":201,"tagName":"p"},{"type":"text","content":"- Selective CBP degrader FHT-171 advancing for the treatment of ER+ breast cancer with IND anticipated in 2027","length":110,"tagName":"p"},{"type":"text","content":"-Selective EP300 degraders with potential in multiple myeloma and other hematological malignancies with IND anticipated in 2027","length":127,"tagName":"p"},{"type":"text","content":"- Strong balance sheet with cash, cash equivalents, and marketable securities of approximately $184 million; cash runway into the first half of 2028","length":148,"tagName":"p"},{"type":"text","content":"WATERTOWN, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today provided a financial and corporate update in conjunction with the Company’s 10-Q filing for the quarter ended March 31, 2026. With an initial focus in oncology, Foghorn’s Gene Traffic Control® Platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.","length":569,"tagName":"p"},{"type":"text","content":"“Our lead program, FHD-909, continues to advance through dose escalation in collaboration with Lilly. The trial is enriching for NSCLC patients with SMARCA4 mutations, whe...